口服羟氨苄青霉素与棒酸钾(Potassium Clavulanate‘PC,一种β-内酰胺酶抑制剂)联合应用将成为第三代头孢菌素强有力的竞争者。这种合剂名为胍丁酰胺(Augmentin)(比切姆公司制造),最近已被食品和药物管理局批准。该药能抗多种革兰氏阳性菌和革兰氏阴性菌,以及梭状芽胞杆菌和拟杆菌属等厌氧菌。合剂应用范围广泛,对于产生或不产生β-内酰胺酶的常见病原体均有效。有关文献记载了临床应用的效果,表明此药可抑制以下产生β-内酰胺酶的细菌:大肠杆 The combination of oral amoxicillin with Potassium Clavulanate (PC), a p-lactamase inhibitor, will be a strong contender for third-generation cephalosporins. This combination, called Augmentin (manufactured by Becum), has recently been approved by the Food and Drug Administration. The drug is resistant to a wide range of Gram-positive and Gram-negative bacteria, as well as anaerobic bacteria such as Clostridium and Bacteroides. Mixtures are widely used and are effective against common pathogens that produce or do not produce beta-lactamases. The literature describes the clinical application of the effect, indicating that the drug can inhibit the following β-lactamase-producing bacteria: colorectal